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Background: To determine diagnostic accuracy of anti–
Saccharomyces cerevisiae antibodies (ASCA) in identifying children
with inflammatory bowel disease (IBD) and to differentiate Crohn’s
disease (CD) from other IBD forms; and to determine the effect of
medical or surgical treatment and of disease location and activity on
ASCA titers.
Methods: Serum samples were obtained from 196 IBD children and
142 controls. ASCA IgA and IgG titers were measured by ELISA.
Measurements were repeated during the follow up of CD children.
Results: ASCA titers were significantly higher in CD than in other
IBD and in control patients. Combination of IgA and IgG ASCA posi-
tivity was highly specific for CD. Medical treatment and disease lo-
cation did not influence assay results. Significantly lower ASCA titers
were obtained in CD children with intestinal resection compared to
CD-affected children who did not undergo surgical resection. ASCA
titers correlated significantly with disease activity, and children with
severe active disease showed higher ASCA values compared to those
in remission. A signficant reduction of ASCA was observed during
the follow-up of CD children when clinical remission was achieved.
Conclusions: The diagnostic accuracy of ASCA is influenced by
disease activity and this suggests an additional use for the follow-up
of CD children of this assay.
Key Words: anti–Saccharomyces cerevisiae antibody, children,
Crohn’s disease, disease activity, inflammatory bowel disease
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The incidence of inflammatory bowel disease (IBD) hasprogressively increased in children in Western countries
during the past few decades.1 The incidence of ulcerative co-
litis (UC) appears to be greater than that of Crohn’s disease
(CD) in Italy and in Scandinavian countries but not in the
United Kingdom, France, and The Netherlands.1 In addition,
most of the retrospective epidemiological studies do not take
into account cases categorized as indeterminate colitis (IC), in
which a definitive diagnosis of CD or UC cannot be made ow-
ing to overlapping or undefined clinical features.1 Thus, IBD
has become an increasingly important diagnostic consider-
ation in pediatric patients presenting nonspecific intestinal
symptoms or extraintestinal manifestations. Unfortunately,
there was a median delay period of 5 months from the onset of
symptoms to diagnosis, and up to 25% of children apparently
suffered symptoms for more than 1 year prior to diagnosis.2
Furthermore, earlier diagnosis may decrease the long-term
morbidity of IBD, which includes delayed puberty and shorter
ultimate height, decreased bone density, nutritional deficien-
cies, and psychologic adjustment to chronic illness.3–5
A lot of progress has been made in gut immunology, in-
flammatory cascades, and genetic susceptibility, yet IBD re-
mains an important challenge to the pediatrician, and clinical
investigation of children with suspected IBD follows a con-
ventional pattern that has not substantially changed in the past
two decades.6 Currently, the diagnosis requires a combination
of typical clinical signs and symptoms, exclusion of other dis-
orders, plus radiographic, endoscopic, and histologic features
consistent with IBD.7–10 Despite careful clinical evaluation, up
to 15% of children with colitis have an indeterminate form, and
up to 4% of patients undergoing colectomy with ileoanal anas-
tomosis for treatment of UC are ultimately determined to have
CD.1,11 Furthermore, the diagnosis of a patient initially iden-
tified as having UC may, over time, be switched to CD due to
an extension of the disease.11 Therefore, readily available,
noninvasive tests are needed to make a timely and accurate
diagnosis of IBD. In addition, the course of IBD is one of re-
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lapse and remission. Thus, another challenge is the difficulty in
predicting relapses or in determining disease activity, and it is
important to identify noninvasive markers for monitoring dis-
ease activity and the effects of treatment.12
Recently, anti–Saccharomyces cerevisiae antibodies
(ASCA) have been increasingly used for the evaluation of pa-
tients with IBD.13 Immunoglobulin (Ig)A and/or IgG ASCA
have been found in 50% to 60% of CD patients, but in only
10% to 15% of UC patients and <5% of healthy controls.11–14
A high diagnostic specificity for CD (>90%) has been re-
ported, with a sensitivity of about 50%. In addition, positive
ASCA titers could be found in unaffected relatives and does
not concord in marital pairs, indicating genetic factors or child-
hood environmental exposure.15 Finally, some data suggests
that ASCA titer may be influenced by disease activity, as it
decreases after damaged gut tissue resection.16 However, more
clinical research is needed to determine the real ASCA clinical
utility in children.
The aims of this study were to investigate the efficacy of
ASCA in identifying children with IBD, to differentiate CD
from the other major forms of IBD, and to determine the effect
of different therapeutic interventions, disease location, and ac-
tivity on ASCA titers in a large cohort of IBD patients and
controls.
MATERIALS AND METHODS
Study Population
Serum was obtained from children attending different
Italian centers of pediatric gastroenterology involved in a na-
tionwide multicenter study approved by the IBD working
group of the Italian Society of Pediatric Gastroenterology and
Hepatology (SIGEP).
The identification of patients for this study was made on
the basis of a clear diagnosis in patients who underwent a com-
plete diagnostic workup for IBD including clinical, radiologic,
endoscopic, and histologic evaluation.10 Whenever possible, a
new serum sample was obtained from the same consenting pa-
tient to evaluate the modification in the ASCA titers during the
course of the disease. All serum samples were stored at –20°C
until assayed and was coded for a blind analysis. Furthermore,
serum was collected from a control group. These children did
not shown evidence or familial history of IBD, immune-
mediated disorders, or immunodeficiencies. Each patient’s
clinical information was collected by investigators unaware of
the results of the antibody profiles. IBD children were classi-
fied as CD or UC according to their diagnosis established by
clinical, endoscopic, histologic, and radiographic standard cri-
teria.10 A third group consisted of patients whose endoscopic
and histologic diagnosis was that of IC, based on the Chong
criteria,17 and confirmed after at least 1-year follow-up. Dis-
ease activity for the groups with CD was calculated by the Pe-
diatric Crohn’s Disease Activity Index (PCDAI)18 and those
with UC by a previously established clinical score.19
The study protocol and consent form were approved by
the Ethics Committee at the Faculty of Medicine of the Uni-
versity ‘Federico II’ of Naples.
Anti–Saccharomyces cerevisiae Antibodies
Determination
Immunoglobulin A and IgG ASCA were determined by
ELISA according to the instruction manuals (Medizym
ASCA, ALIFAX, MEDIPAN Diagnostic, Selchow, Ger-
many), as previously described.13,20 The cutoff for ASCA IgA
and IgG positivity was set at 20 U/mL as determined by the
company on the basis of the results in well-defined patients
with CD.
Statistical Analysis
Statistical analysis was performed using the SPSS soft-
ware version 10.0.7 for Windows. In addition to the sensitivity
and specificity test, the statistical analysis was based on the
study of the differences between groups concerning IgA and
IgG ASCA levels in IBD children and in controls. The 2 test
was used to compare qualitative variables between groups.
Analysis of variance (ANOVA) was used to compared IgA and
IgG ASCA titers among groups. Adjustment for multiple com-
parisons was made using the Bonferroni correction or the Dun-
net’s T3 test. The Student’s t test was used to evaluate the dif-
ferences in ASCA titers in patients who had undergone intes-
tinal resection and during the follow-up of CD children. A p
value <0.05 was considered significant. Linear regression
analysis was used to evaluate correlations.
RESULTS
Patient Population
Sera were collected from 329 subjects divided in 4
groups: controls, CD, UC, and IC children. Informed consent
was obtained from each subject. The control group consisted
of a total of 142 children, all with no family history of IBD and
no immune-mediated disorders or immunodeficiencies: 98
with extraintestinal disorders (mainly patients with respiratory
tract infection), and 44 with non-IBD intestinal illness. This
subgroup consisted of children with acute viral gastroenteritis
(n = 16), irritable bowel syndrome (n = 8), gastroesophageal
reflux (n = 6), Helicobacter pylori gastritis (n = 5), allergic
colitis (n = 3), pseudomembranous colitis, polyposis, and acute
self-limiting colitis (n = 2 each). The demographic character-
istics of the study groups were similar, and are reported in
Table 1. Further clinical characterization of IBD patient
groups is shown in Table 2.
Anti–Saccharomyces cerevisiae Antibodies
Determination
The IgA and IgG ASCA titers in IBD and non-IBD chil-
dren are reported in Figure 1. Comparison of ELISA results
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showed that the mean ASCA levels were significantly higher
in CD than in UC, IC, and control groups. The combination of
IgA and IgG ASCA positivity was highly specific for CD, with
60 out of 102 (58.8%) patients with CD being IgA or IgG posi-
tive, compared with only 5 out of 47 (10.6%) with UC, and 3
out of 38 (7.8%) with IC (Table 3). Positive titers of ASCA IgA
or IgG were found in 5 out of 142 control children (3.5%). The
combination of IgA and IgG ASCA positivity was observed in
none of the UC patients and controls, and in only 1 out of 38 IC
patients.
Influence of Medical and Surgical Therapy
In CD children, the use of different medical therapeutic
options: anti-inflammatory (mesalamine or sulfasalazine) (n =
30, 14 with active disease), immunosuppressive drugs (meth-
ylprednisolone or azathioprine) (n = 34, 19 with active dis-
ease), and nutritional therapy (n = 4, all with active disease) did
not have an impact on ASCA assay results compared with
those obtained in untreated patients (n = 34, 23 with active
disease and 8 with an unknown PCDAI at the time of serum
sampling).
Among CD children, 13 out of 102 (12.7%) had under-
gone an intestinal resection. Ten of these, all in clinical remis-
sion (PCDAI score  10), showed negative ASCA titers
(mean interval between surgery and testing = 2.5 years). On the
other hand, 3 patients, all with moderate active disease (PC-
DAI score between 11 and 30), were positive for ASCA IgG or
IgA (mean interval between surgery and testing = 35 days).
However, the mean ASCA titers were significantly lower in
CD patients with intestinal resection compared with CD chil-
dren who did not undergo surgical resection (29.6 ± 9.5 vs 44.2
± 5.3 and 23.6 ± 7.0 vs 52.6 ± 6.7, IgA and IgG ASCA, respec-
tively, means ± 95% CI, p < 0.05).
Influence of Disease Location
No significant relationship was found between ASCA
titers and the site of CD inflammation (small versus large
FIGURE 1. IgA and IgG ASCA values in the different study
groups. Dare are means  95% CI. *p < .001, CD versus UC,
IC, or controls.
TABLE 2. Clinical Characteristics of IBD Children
CD UC IC
n 102 47 38
Mean disease duration (months) 26.8 21.8 22.5
Location
Small bowel 36
Colon 12 47 38
Small bowel and colon 54
Activity
Active/inactive 53/41* 26/21 25/13
CD, Crohn’s disease; UC, ulcerative colitis; IC, indeterminate colitis.
*In 8 CD patients, the PCDAI score was unknown at the time of serum
sampling.
TABLE 3. Diagnostic Accuracy of ASCA To Distinguish
Between CD, UC, IC, and non-IBD Children
CD vs Other IBD
+ Non-IBD
Sensitivity
(%)
Specificity
(%)
P.P.V.
(%)
N.P.V.
(%)
IgA+ 48/102 220/227 48/55 220/274
(47.1) (96.9) (87.3) (80.3)
IgG+ 58/102 215/227 58/70 215/259
(56.9) (94.7) (82.9) (83.0)
IgA+ or IgG+ 60/102 210/227 60/77 210/252
(58.8) (92.5) (77.9) (83.3)
IgA+ and IgG+ 46/102 225/227 46/48 225/281
(45.1) (99.1) (95.8) (80.1)
CD, Crohn’s disease; UC, ulcerative colitis; IC, indeterminate colitis;
P.P.V., positive predictive value; N.P.V., negative predictive value.
TABLE 1. Demographic Data in Controls and in CD, UC,
and IC Children
Controls CD UC IC
n 142 102 47 38
Sex
Male 82 60 24 20
Female 60 42 23 18
Age (years)
Mean 8.1 12.9 10.8 9.9
SD 3.3 4.1 3.8 3.5
Range 1–17 1–19 2–18 1–19
CD, Crohn’s disease; UC, ulcerative colitis; IC, indeterminate colitis.
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bowel involvement, or both). However, patients with active
CD limited to the colon tended to have lower IgA and IgG
ASCA titers compared with others with CD involving only the
small intestine (p = 0.86).
Influence of Disease Activity
To evaluate the effect of disease activity on ASCA titers
in CD patients, we divided the children in subgroups according
to the PCDAI score determined at the time of serum sampling.
Thus, we obtained the following three subgroups: (1) remis-
sion (PCDAI score  10, n = 41); (2) moderate activity
(PCDAI score between 11 and 30, n = 28); (3) severe activity
(PCDAI score > 30, n = 25). Eight CD patients were excluded
from this evaluation because the PCDAI score was unknown at
the time of serum sampling. As reported in Figure 2, an in-
creasing IgA and IgG ASCA titer pattern was obtained in
agreement with disease activity. Children with severe active
CD (PCDAI score > 30) showed significantly higher values
compared with patients in clinical remission (PCDAI score 
10). On the contrary, no significant difference in ASCA titers
was observed between patients in clinical remission (PCDAI
 10) and patients with moderate disease activity (PCDAI 11–
30). In addition, as shown in Figure 3, ASCA titers showed a
significant correlation with the PCDAI score. Moreover, as re-
ported in Table 4, the diagnostic accuracy of ASCA for CD
was highly improved when we considered patients with active
disease.
Determination of Anti–Saccharomyces cerevisiae
Antibodies During the Follow-up of
CD Children
To investigate further the influence of disease activity on
the ASCA titers, we performed a double determination in 20
CD patients. The first was done during the active phase of CD
and the second, after 10 weeks of exclusive nutritional therapy
FIGURE 2. Effect of disease activity (determined by the PCDAI
score) on IgA and IgG ASCA titers in CD children. Dare are
means9 5% CI. *p < 0.001, patients with a PCDAI score > 30
versus children with a PCDAI score  10.
FIGURE 3. Linear regression function showing a significant correlation between disease activity (determined by the PCDAI score)
and both IgA and IgG ASCA in CD children (p < 0.05).
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with a polymeric formula (Modulen, Nestlè, Italy), when the
clinical remission was achieved (PCDAI score  10). The re-
sults are reported in Figure 4. A significant reduction of both
IgA and IgG ASCA titers was observed for all patients.
DISCUSSION
The onset of pediatric IBD is frequently insidious and
presents nonspecific or overlapping symptoms, which often
results in missed or delayed diagnosis as well as in the overuse
of invasive diagnostic tests.1 The central immunologic contri-
bution to the pathogenesis of IBD stimulated the search for
antibodies and associated antigens in the hope that this would
reveal a specific pathogenic mechanism for IBD. However, at
the present time, IBD-associated antibodies have not been
found to mediate pathogenic events.21 Although such antibod-
ies are not of direct pathogenic importance, their level of
specificity for either UC or CD suggests that they cannot be
considered as entirely nonspecific secondary responses to
mucosal injury or inflammation.21 Instead, they suggest an im-
mune dysfunction or reflect a cross-reactivity with environ-
mental factors, including intestinal microflora.22 Another po-
tential role for IBD associated antibodies is their use in sub-
stratifying unclear disease phenotypes like IC as either UC
or CD or in classifying disease subtypes with different ge-
netic associations.1 The ASCA and perinuclear antineutrophil
cytoplasmic antibodies (pANCA) have been the two most in-
tensely studied antibodies in the substratification of IBD
patients.13
We used a well-established ELISA ASCA assay that had
recently been evaluated in a large comparative study.13 Our
results confirm that ASCA are helpful in the diagnosis of pe-
diatric CD showing a high specificity and positive predictive
values in discriminating CD versus other IBD forms. Further-
more, in agreement with other reports,15,22 our results suggest
that both medical therapy and disease location did not influ-
ence ASCA titers. However, children with CD involving the
small intestine tended to have higher ASCA titers compared
with other CD patients, but larger populations of children are
needed to draw conclusions on this issue.
In contrast to constant pANCA values after colectomy in
UC patients, it has been suggested that ASCA titers may be
reduced after intestinal resection in CD patients.16 Our results
support these findings, but it could be important to note that all
but 3 CD children who underwent intestinal resection were in
clinical remission when ASCA values were determined and
this suggests the possible influence of disease activity on
FIGURE 4. Modifications of ASCA IgA and IgG titers during the
follow up of CD children. A double determination of ASCA
titers was performed in 20 CD patients: the first was done
during the active phase of CD (PCDAI score > 30) and the
second, after 10 weeks of nutritional therapy, with a polymeric
formula, when a clinical remission was achieved (PCDAI score
 10). A significant reduction of both IgA and IgG ASCA titers
was observed (p < 0.05).
TABLE 4. Modifications of the Diagnostic Accuracy of ASCA
To Distinguish Between CD Versus non-IBD Children
According to PCDAI
Sensitivity
(%)
Specificity
(%)
P.P.V.
(%)
N.P.V.
(%)
PCDAI 10 (n = 41)
IgA+ 6/41 140/142 6/8 140/175
(14.6) (98.6) (75.0) (80.0)
IgG+ 12/41 139/142 12/15 139/168
(29.3) (97.9) (80.0) (82.7)
IgA+ or IgG+ 12/41 137/142 12/17 137/166
(29.3) (96.5) (70.6) (82.5)
IgA+ and IgG+ 6/41 142/142 6/6 142/177
(14.6) (100.0) (100.0) (80.2)
PCDAI 11–30 (n = 28)
IgA+ 16/28 140/142 16/18 140/152
(57.1) (98.6) (88.9) (92.1)
IgG+ 18/28 139/142 18/21 139/149
(64.3) (97.9) (85.7) (93.3)
IgA+ or IgG+ 19/28 137/142 19/24 137/146
(67.9) (96.5) (79.2) (93.8)
IgA+ and IgG+ 15/28 142/142 15/15 142/155
(53.6) (100.0) (100.0) (91.6)
PCDAI >30 (n = 25)
IgA+ 21/25 140/142 21/23 140/144
(84.0) (98.6) (91.3) (97.2)
IgG+ 23/25 139/142 23/26 139/141
(92.0) (97.9) (88.5) (98.6)
IgA+ or IgG+ 24/25 137/142 24/29 137/148
(96.0) (96.5) (82.8) (99.3)
IgA+ and IgG+ 20/25 142/142 20/20 142/147
(80.0) (100.0) (100.0) (96.6)
CD, Crohn’s disease; PCDAI, Pediatric Crohn’s Disease Activity Index;
P.P.V., positive predictive value; N.P.V., negative predictive value.
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ASCA titers. Moreover, in our study at least two lines of evi-
dence suggest a further relationship between disease activity
and ASCA values. The first is represented by the significantly
higher titers obtained in severe active CD compared with those
measured in patients in clinical remission. The second is the
decreasing pattern of ASCA titer observed in all CD children
tested serially when the disease was active and then when clini-
cal remission was achieved. Finally, linear regression analysis
showed a significant correlation between ASCA titers and
PCDAI score. These findings are seemingly in contrast with a
previous observation showing higher but not statistically sig-
nificant IgG ASCA titer in children with active CD compared
with those observed in subjects in remission.16 However, it is
possible that the smaller population of active CD patients pre-
viously analyzed (21/119, 18.0%), compared with the larger
number of the present observation (53/94, 56.3%) could ac-
count for this discrepancy. The relationship between disease
activity and ASCA titers, observed in this study, suggests that
this assay could be used to evaluate disease activity in CD chil-
dren. The course of CD is one of relapses and remissions. The
evaluation of disease activity using a specific marker may help
in the differential diagnosis of nonspecific symptoms. Measur-
ing ASCA, together with standard parameters and emerging
activity markers such as calprotectin in stools23 and nitric ox-
ide in rectal dialysate fluid,24 could be useful in monitoring the
disease course and response to treatment in CD children. In
addition, it has been recently suggested that high levels of both
IgA and IgG ASCA titers could be associated with a greater
necessity for small bowel surgery, because of stricturing or
perforating complications, in CD patients.7 Similar observa-
tions were reported in patients with mutations in the
CARD15/NOD2 gene who are more likely to develop fibro-
stenosing disease of the small bowel.25 These considerations
could have important implications for disease subtype stratifi-
cation.
Finally, the influence of disease activity on ASCA titers
could contribute to an improvement of the diagnostic accuracy
of this assay. Considering all CD patients together, we ob-
tained a low sensitivity, similar to that obtained in other stud-
ies.11,13,16 On the contrary, when we compared only active CD
patients with controls or others IBD forms, we obtained a sig-
nificant improvement in sensitivity (up to 96%), without a sig-
nificant decrease in specificity. Thus, the sensitivity of ASCA
is higher in children with active CD, which represents the ma-
jor diagnostic dilemma for pediatricians.
In conclusion, together with a high diagnostic specificity
and sensitivity for active forms of CD in pediatric patients,
ASCA antibodies could provide another noninvasive tool for
guiding medical management of CD children.
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